Rheumatoid Arthritis

Increased presence of myocardial inflammation in patients with rheumatoid arthritis could be treated with non-TNFi biologic disease modifying anti-rheumatic drugs.

The proportion of specific inflammatory proteins can influence treatment outcomes.

Patients with RA may be overwhelmed by information about disease-modifying antirheumatic drugs.

There is a need for the surgeons and prescribing rheumatologists to jointly address complications they may cause in RA patients.

The relationship between heart disease and rheumatoid arthritis needs deeper examination.

The amount of information patients receive about disease-modifying anti-rheumatic drugs may overwhelm their memory.

New research is needed to determine proper diagnostic measurements for sarcopenia.

Distinct subsets of synovial fibroblasts in rheumatoid arthritis development identified.

Top news of the week on Specialty Pharmacy Times.

Rheumatic and myocardial inflammation can be treated with disease modifying anti-rheumatic drugs.

Rapid reduction of rheumatoid arthritis symptoms rated as the most important factor in choosing a treatment.

Patients with early stage rheumatoid arthritis may benefit from tapering DMARD therapy.

Naturally-occurring genetic variants may improve autoimmune disease treatment.

Biosimilars can provide an easily accessible, low cost treatment option for patients with rheumatoid arthritis.

Baricitinib is a once-daily oral selective JAK1 and JAK2 inhibitor for the treatment of autoimmune and inflammatory diseases.

Ingredient in aspirin combined with popular diabetes drug can turn off faulty protein that plays a key role in inflammatory diseases, such as rheumatoid arthritis.

Growing evidence points to the relationship between rheumatoid arthritis and heart problems.

IL-1 antagonists are traditionally used to treat patients with rheumatoid diseases.

Two TNF-inhibitors found equally effective treating RA patients.

Researchers able to predict treatment response to TNFI drugs and rituximab in RA patients.

Growing evidence points to the relationship between rheumatoid arthritis and heart problems.

Patients with rheumatoid arthritis want a fast-acting, orally administered treatment for their symptoms.

A better understanding of the mechanisms of arthritis is needed to develop superior treatments.

Baricitinib significantly improved patient-reported outcomes in individuals with RA.

Study compares the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.